Zynex Monitoring Solutions
$546.3K 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Shield Therapeutics Inc
Shield Therapeutics Inc reported $548,739.17 across General Payments, Research, and Ownership to 21,623 physicians and teaching hospitals across 21,623 transactions.
- $548.7K Above-median payer
- All-tracks total
- 21,623 Top 10% volume
- Transactions
- 21,623 Top 10% reach
- Recipients
- +$94.8K
- General Payments vs PY2023
Shield Therapeutics Inc reported $548,739.17 across all CMS Open Payments tracks (General + Research + Ownership) to 21,623 physicians and teaching hospitals in Program Year 2024 - ranking #742 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $548,739.17, averaging $25.38 per recipient.
Shield Therapeutics Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
66/100
Total payments
F
15/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer shield-therapeutics-inc Shield Therapeutics Inc
$548.7K · #742/1,925 · 0.0% industry · PY2024
- TOT $548.7K
- RANK #742
- SHARE 0.0%
- TXN 21,623
- RCP 21,623
- CAT 4
- GEN $548.7K
- ΔGEN +$94.8K
- TOP1 2.2%
- PY 2024
Volume peers
Nearest volume peer: Zynex Monitoring Solutions ($546.3K)
Shield Therapeutics Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Shield Therapeutics Inc's CMS-reported General Payments increased by $94.8K (+20.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SHIELD THERAPEUTICS INCPY2023: SHIELD THERAPEUTICS INCPY2024: SHIELD THERAPEUTICS INC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $453,981.11
- PY2024
- $548,739.17
What the Data Shows for Shield Therapeutics Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Shield Therapeutics Inc that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Food and Beverage" leads the 4-category general-payment breakdown below at $532.8K (97.1% of General Payments, 21,617 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 4 types of general payments, Shield Therapeutics Inc's largest category was "Food and Beverage" at $532.8K - 97.1% of General Payments.
Shield Therapeutics Inc reports 4 general-payment categories - the top three are Food and Beverage (97.1%), Compensation for Services Other Than Consulting (1.5%), and Honoraria (0.8%). The remaining 1 category make up 0.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Shield Therapeutics Inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $532.8K | 21,617 | 97.1% |
| Compensation for Services Other Than Consulting | $8.0K | 2 | 1.5% |
| Honoraria | $4.4K | 2 | 0.8% |
| Travel and Lodging | $3.5K | 2 | 0.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $17,887.82 (3.3%) of $548,739.17 in this company's General Payments records across 12,134 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Shield Therapeutics Inc
The five named recipients with the highest reported General Payments from this company
- 1
David L Adler
$12,227.64 across 9 reported transactions
- 2
Rochelle Nazarian
$4,081.54 across 20 reported transactions
- 3
Brian J Sprandio
$566.59 across 12 reported transactions
- 4
Sarah Elaine Eplion
$514.15 across 6 reported transactions
- 5
Kathryn Elise Parris
$497.90 across 10 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Shield Therapeutics Inc ranks #742 of 1,925 by total payments (top 39% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,833 of 1,838 by HHI (bottom 1% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- E.R. Squibb & Sons, L.L.C. : $31.0M total payments, HHI 12
- Aspira Women's Health Inc : $74.7K total payments, HHI 12
- Corium, LLC : $1.7M total payments, HHI 11
- Novo Nordisk Inc : $25.5M total payments, HHI 9
- Beta Bionics, Inc. : $243.6K total payments, HHI 8
- Innovation Technologies Inc : $205.0K total payments, HHI 8
- Shield Therapeutics Inc (this company) : $548.7K total payments, HHI 7
- Evofem Biosciences, Inc. : $90.0K total payments, HHI 7
- Noven Therapeutics, LLC : $197.9K total payments, HHI 4
- Millicent US Inc : $137.2K total payments, HHI 4
- Kowa Pharmaceuticals America, Inc. : $101.9K total payments, HHI 3
- Cranial Technologies, Inc : $268.9K total payments, HHI 1
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Shield Therapeutics Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Shield Therapeutics Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Shield Therapeutics Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Amaros, Inc.
$551.3K 0 recipients
Compare payment profiles
Leica Microsystems (Schweiz) AG
$553.3K 18 recipients
Compare payment profiles
Hu-Friedy Mfg. Co., LLC
$554.1K 2,442 recipients
Compare payment profiles
OraPharma, a division of Bausch Health US, LLC
$539.1K 7,610 recipients
Compare payment profiles
Aesculap Biologics, LLC
$559.6K 11 recipients
Compare payment profiles
Put this to use
Shield Therapeutics Inc ranks #742 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Shield Therapeutics Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.